Advances in immunotoxins

T N Oeltmann1, A E Frankel

  • 1Department of Medicine, Vanderbilt Medical School, Nashville, Tennessee 37232.

The field of immunotoxins is continuing to grow, as shown by the increase in attendance (175 vs. 145) and abstracts (110 vs. 60) at the symposium. Advances in the molecular biology of the toxins and clinical applications were notable at this meeting. The next 2 years should see better definition of the mechanism of action of peptide toxins as well as improvements in the design of targeted toxins for potential therapy of a wide variety of human diseases.

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...